All In Biotech

Free tool

FAERS Monitor: Segluromet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209806 or its brand name (Segluromet, Ertugliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

82

Serious

29

35% of reports

Hospitalization

16

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue11
  • no adverse event8
  • nausea7
  • diabetic ketoacidosis6
  • vomiting6
  • asthenia5
  • diarrhoea4
  • inability to afford medication4
  • blood glucose increased3
  • decreased appetite3
  • drug ineffective3
  • inappropriate schedule of product administration3
  • influenza3
  • product dose omission3
  • product use issue3

Reports by year received

View as table
YearReports
20186
201924
202010
202115
202210
20236
20246
20253
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,077 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
inability to afford medicationSignal4103.439.7310
diabetic ketoacidosisSignal664.129.7312
product dose omissionSignal311.83.920
no adverse eventSignal811.35.966
product dose omission issueSignal119.65.577
influenzaSignal36.92.310
inappropriate schedule of product administrationSignal34.31.45
product use issueSignal34.11.34
blood glucose increasedSignal34.11.34
astheniaSignal53.41.56
decreased appetite33.31.13
vomitingSignal63.31.58
nausea72.31.14
diarrhoea41.60.60
drug ineffective30.60.21

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.